Trade Denali Therapeutics - DNLI CFD

Trading Conditions

• TypeThis financial market is available for CFD trading.Learn more about:CFDs: CFD
• Spread: 0.09
• Long position overnight funding adjustmentLong position overnight funding adjustmentMargin. Your investment$1,000.00Overnight funding adjustmentCharges from full value of position-0.022262 %(-$4.45)Trade size with leverage ~ $20,000.00Money from leverage ~ $$19,000.00Go to platform: -0.02226%
• Short position overnight funding adjustmentShort position overnight funding adjustmentMargin. Your investment$1,000.00Overnight funding adjustmentCharges from full value of position0.00004 %($0.01)Trade size with leverage ~ $20,000.00Money from leverage ~ $$19,000.00Go to platform: 0.00004%
• Overnight funding adjustment time: 21:00 (UTC)
• Currency: USD
• Min traded quantity: 1
• Margin: 5.00%
• Stock exchange: United States of America
• Commission on trade: 0%
• Guaranteed stop premiumA guaranteed stop-loss (GSL) fee is only charged if the GSL is triggered. Please consult the Charges and Fees section of our website for more details.: 1%

• Margin. Your investment: $1,000.00
• Overnight funding adjustmentCharges from full value of position: -0.022262 %
  (-$4.45)

• Margin. Your investment: $1,000.00
• Overnight funding adjustmentCharges from full value of position: 0.00004 %
  ($0.01)

Key Stats

• Prev. Close: 20.35
• Open: 19.76
• 1-Year Change: 42.77%
• Day's Range: 19.76 - 21.2

Trade Denali Therapeutics - DNLI

About Denali Therapeutics Inc

Denali Therapeutics Inc. is a biopharmaceutical company. The Company is focused on the discovery and development of therapies for patients with neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS) and others. The Company clinical programs include leucine-rich repeat kinase 2 (LRRK2) inhibitor program, eukaryotic initiation factor 2 B (EIF2B) activator program, enzyme transport vehicle: iduronate 2-sulfatase (ETV:IDS) program, receptor interacting serine/threonine protein kinase 1 (RIPK1) inhibitor program and second non-CNS penetrant RIPK1 inhibitor. The Company engineers its product candidates to cross the blood-brain barrier (BBB), and act directly in the brain. Its pipeline includes approximately 15 programs that are based on its TV technology, including the lead program ETV:IDS (DNL310). Its product pipeline includes DNL151, DNL593 (PTV:PGRN), DNL126 (ETV:SGSH), DNL788, DNL343, DNL758,

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Denali Therapeutics Inc revenues decreased 86% to $48.7M. Net loss totaled $290.6M vs. income of $71.1M. Revenues reflect Other collaboration revenue decrease of 96% to $4K. Net loss reflects Research & Development Expense - Balanci increase of 17% to $215.3M (expense), Stock-based Compensation in R&D increase of 73% to $50M (expense).